`
`Case 1:18-cv-01363-CFC Document 57 Filed 01/11/19 Page 1 of 1 PageID #: 8169
`
`
`
`
`
`
`
`
`
`Frederick L. Cottrell, III
`302-651-7509
`Cottrell@rlf.com
`
`January 11, 2019
`
`VIA ELECTRONIC FILING
`The Honorable Colm F. Connolly
`U.S. District Court for the District of Delaware
`J. Caleb Boggs Federal Building
`844 N. King Street, Unit 31, Room 4124
`Wilmington, DE 19801-3555
`
`Re: Herceptin Litigation: Genentech v. Amgen, C.A. No. 18-924-CFC; Genentech, Inc. &
`City of Hope v. Samsung Bioepis Co., Ltd., C.A. No. 18-1363-CFC
`
`Dear Judge Connolly,
`
`
`I write on behalf the parties regarding the joint appendix of intrinsic evidence for claim
`construction previously filed in these cases on December 11, 2018. See C.A. No. 18-924-CFC,
`D.I. 60-1 through 60-14; C.A. No. 18-1363-CFC, D.I. 48-1 through 48-14.
`
`Subsequent to the filing of the joint appendix, the Patent Office issued U.S. Patent No.
`
`10,160,811 (“the ’811 patent”) to Genentech. After the corresponding patent application was
`allowed, Genentech notified the defendants of its intention to assert this patent in the case.
`Genentech is adding this newly-issued patent to the case through amended complaints, and the
`parties will address a term from the ’811 patent in their claim construction briefing.
`
`To facilitate claim construction briefing, and consistent with the Court’s requirements for
`
`claim construction appendices, the parties wish to submit a supplemental joint appendix that
`includes a copy of the ’811 patent. A copy of this supplemental joint appendix is attached to this
`letter. Please let us know if the Court prefers that the parties submit this material in a different
`format.
`
`
`Respectfully,
`
`/s/ Frederick L. Cottrell, III
`
`Frederick L. Cottrell, III (#2555)
`
`
`cc: All Counsel of Record (via email)
`
`RLF1 20632171v.1
`ACTIVE/98023071.1
`
`
`